High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
Raphael KochAndré B P van KuilenburgLianne M HavemanBenedicte BrichardHeribert JürgensSona CyprovaHenk van den BergWolf HassenpflugAnna RaciborskaTorben EkDaniel BaumhoerGerlinde EgererHans Theodor EichMarleen RenardPéter HauserStefan BurdachJudith BoveeFiona BonarPeter ReichardtJarmila KruseováJendrik HardesThomas KuhneTorsten KesslerStéphane CollaudMarie BernkopfTrude Butterfaß-BahloulCatharina DhoogeSebastian BauerJános KissMichael PaulussenAngela HongAndreas RanftBeate TimmermannJelena RasconVolker ViethJukka KanervaAndreas FaldumMarkus MetzlerWolfgang HartmannLars HjorthVivek BhadriUta DirksenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In patients with very high-risk EWS, additional TreoMel-HDT was of no benefit for the entire cohort of patients. TreoMel-HDT may be of benefit for children age < 14 years.